Arbutus Biopharma Corp ABUS
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
3/9
Piotroski F — financial health
-39.67
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $14.1M | -$33.5M | — | -$39.6M | $76.6M |
| 2024 | $6.2M | -$69.9M | — | -$65.0M | $97.4M |
| 2023 | $18.1M | -$72.8M | — | -$86.9M | $106.0M |
| 2022 | $39.0M | -$69.5M | — | -$35.9M | $136.9M |
| 2021 | $11.0M | -$76.2M | — | -$68.3M | $169.4M |
| 2020 | $6.9M | -$63.7M | — | -$51.7M | $102.0M |
Why these scores methodology →
Piotroski F-score: 3/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -39.67 (distress)
- Working capital / assets 0.935
- Retained earnings / assets -14.586
- EBIT / assets -0.403
- Equity / liabilities 4.244
Source: SEC EDGAR filings · CIK 0001447028 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.